French Nano-Xrays to Kill Prostate Cancer in Phase I/II Trial

04/01/2016 - 3 minutes

A Parisian Nanomedicine biotech is using it’s proprietary NanoXray technology to enhance radiotherapy. Now a candidate to treat Prostate cancer has received FDA approval for a phase I/II trial in the US.

nanobiotix_radiotherapy_trial_prostate_cancer_nanomedicine_franceNanobiotix is seeking to develop NBTXR3 for patients with intermediate and high-risk prostate cancer, with the aim of providing effective tumor destruction and disease control.

As a spin-off of the State University of New York (SUNY), Nanobiotix was founded in 2003, but with it’s HQ in Paris and primary funding from European VCs. We also interviewed their CEO, Laurent Levy, back in April.

Since 1 in 7 men are diagnosed with prostate cancer and it is the second leading cause of cancer death in the US (according to the American Cancer Society), a potential enhancer of existing radiotherapeutics is a smart way to tackle the disease.

This is because radiation must first pass through healthy tissues before reaching the tumor target,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member